Verastem announces launch of Reimagine Recurrent LGSOC campaign

Verastem (VSTM) Oncology announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer, LGSOC, campaign for Avmapki Fakzynja Co-Pack, the first and only treatment specifically approved by the U.S. Food and Drug Administration, FDA, for adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy. The integrated campaign encourages healthcare professionals and patients to rethink what may be possible at and beyond the earliest recurrence for people living with KRAS-mutated recurrent LGSOC.